Research programme: CNS cancer therapeutics - Angiochem/Geron Corporation
Latest Information Update: 07 Dec 2012
At a glance
- Originator AngioChem; Geron Corporation
- Class Drug conjugates; Oligonucleotides; Peptides
- Mechanism of Action Telomerase inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Brain cancer